Common questions about Pergoveris (FAQ)
Q: Why is Pergoveris prescribed for women with severe LH and FSH deficiency?
Official documents state that Pergoveris is indicated for the stimulation of follicular development in adult women who have a severe deficiency of both Luteinising Hormone (LH) and Follicle-Stimulating Hormone (FSH). This patient population requires both hormones for successful ovarian function, and the medication is used to provide this essential hormonal support.
Q: Are there any early signs of OHSS a patient should be aware of while taking Pergoveris?
The official product information explains that symptoms of mild to moderate Ovarian Hyperstimulation Syndrome (OHSS) may include mild-to-moderate abdominal pain, abdominal bloating, nausea, or vomiting. If a patient experiences these symptoms, they are generally directed to contact their healthcare team immediately.
Q: Is there information available on the long-term safety profile of Pergoveris?
Regulatory reviews assess the safety profile based on clinical trials and ongoing post-marketing surveillance to monitor for any new safety signals. A definitive, long-term safety statement beyond the follow-up period of clinical trials is not typically documented in official labeling.
Q: Is Pergoveris use contraindicated if a person has certain hormone-dependent tumors?
Yes, the medication is contraindicated (should not be used) if a patient has sex hormone-dependent tumors of the reproductive tract, accessory organs, or tumors of the pituitary gland or hypothalamus. These specific conditions prevent the safe use of the medicine.
Q: Can Pergoveris be used by people with a family history of porphyria?
Regulatory guidance states that patients with porphyria or a family history of porphyria should be closely monitored during treatment. Official documentation notes that if the condition deteriorates, cessation of treatment may be required by the prescribing professional.
Q: What kind of results can a patient generally expect in terms of egg retrieval numbers with Pergoveris?
Clinical trial data indicates that the use of Pergoveris is associated with successful follicular development and a consistent number of retrieved oocytes in the patient populations studied. The specific outcome observed will be based on an individual patient’s response during their monitored cycle.
Q: Is the fixed-dose ratio of FSH and LH in Pergoveris suitable for all women with severe deficiency?
Pergoveris is formulated to provide a fixed ratio of FSH and LH, designed for initial treatment. However, official information notes that the treatment regimen is tailored to the individual patient’s response, which may involve adjusting and increasing the FSH dose using a separate preparation.
Q: What are the potential signs of an allergic reaction to Pergoveris?
Allergic reactions to the medicine are considered very rare. The potential signs of an allergic reaction described in patient information can include skin reactions such as rash, red skin, or hives, or more serious signs like swelling of the face or difficulty breathing.
Q: What are the two active ingredients in Pergoveris and what do they mimic?
The two active ingredients are follitropin alfa and lutropin alfa. These ingredients are recombinant copies of the body’s natural hormones, Follicle-Stimulating Hormone (FSH) and Luteinising Hormone (LH), which are naturally secreted by the pituitary gland.
Q: Why is Pergoveris not recommended during pregnancy or breastfeeding?
The medicine is strictly contraindicated for use during pregnancy or breastfeeding. Official information notes that the frequency of pregnancy loss is higher in patients undergoing ovarian stimulation treatments, and an effect of the medicine on birth defects has not been excluded.
Q: Is Pergoveris only available in a pre-filled pen format?
Official product documentation confirms that Pergoveris is available in two formats. It is supplied as a solution for injection in a pre-filled pen and also as a powder and solvent that must be mixed to create the solution for injection.
Q: Is there an interaction risk with common non-prescription medicines or supplements while using Pergoveris?
Regulatory information does not specifically list documented interaction patterns for co-administration with common non-prescription medicines or supplements. The active ingredients are protein-based and are not expected to interact with other small-molecule medicines through the major metabolic pathways.
Q: Does the use of Pergoveris affect a patient's ability to drive or operate machinery?
Official patient information states that the medicine is not expected to affect the ability to drive or use heavy machinery. However, as with many medicines, patients typically exercise caution until they know how the medication affects them.
Q: Is there an age limit or defined age range for women who are prescribed Pergoveris?
The medication is indicated for use in adult women. Regulatory documents state that safety and efficacy have not been established in either the paediatric (children) or the elderly patient populations.
Q: Can Pergoveris be used concurrently with other fertility treatments?
The official prescribing information notes that co-administration or sequential use with other agents for ovarian stimulation, particularly Human Chorionic Gonadotropin (hCG), results in an expected additive effect. Pergoveris is used as a component within a larger assisted reproductive technology (ART) protocol.
Q: What is the official position on using Pergoveris if a patient has uncontrolled thyroid or adrenal problems?
Official documentation indicates that existing thyroid, adrenal, or prolactin disorders need to be appropriately addressed and managed prior to beginning therapy.
Q: What is the reason for using a barrier method of contraception if OHSS is developing during treatment?
In the event Ovarian Hyperstimulation Syndrome (OHSS) is developing, official protocols may include refraining from sexual intercourse or using a barrier contraceptive method. This measure is described in labeling as a protocol to prevent pregnancy in a cycle classified as high-risk for severe OHSS.
